OCS — Oculis Holding AG

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1953530 ·
Last close
$7.51
Market Cap
$417.01M
52W High
$34.47
52W Low
$6.78
ADV30
316,030
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -23,638,000 -18,236,000 232,318,000 66,292,000 23,566,000
Jun 2026 0 — -23,568,000 -9,970,000 250,335,000 61,614,000 30,998,000
Mar 2026 0 — -21,728,000 -28,852,000 243,993,000 64,564,000 47,345,000
Dec 2025 0 — -20,633,000 -23,514,000 235,963,000 81,329,000 39,893,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-71,212,000
Investing CF
$-43,833,000
Financing CF
$131,750,000
CapEx
$-183,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.37
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-441,572,000
Inventory
—
Receivables
$1,920,000
ST Investments
$143,999,000
EBIT TTM
$-79,794,000
Pretax Income TTM
$-80,888,000
Interest Exp TTM
$1,094,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,173,000
EBITDA
$-85,977,000
Free Cash Flow
$-41,372,752
Enterprise Value
$426,109,600
Total Cash
$228,324,000
Total Debt
$2,543,000
Shares Out
55,527,961
Trailing EPS
$-1.70
Book Value
$4.35
ROE
-43.7%
ROA
-25.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -81,672,000 -98,957,000 235,963,000 39,893,000 196,070,000 -66,304,000
Dec 2024 0 -73,204,000 -85,777,000 120,353,000 46,970,000 73,383,000 -48,919,000
Dec 2023 0 -45,851,000 -88,802,000 114,353,000 20,625,000 93,728,000 -55,037,000
Dec 2022 0 -32,376,000 -38,698,000 37,060,000 135,051,000 -97,991,000 -25,074,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.02

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.50 · spot: $7.39 · call volume: 2 · put volume: 17
Expected Move to 2027-02-19: ±$3.60 (48.71%) — implied range $3.79 – $10.99 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
OVID Ovid Therapeutics Inc. $418.98M $2.22 —
AVTX Avalo Therapeutics, Inc. $412.28M $7.13 —
CTMX CytomX Therapeutics, Inc. $422.93M $1.94 —
PRTA PROTHENA CORP PUBLIC LTD CO $424.15M $8.26 —
PTCHF PureTech Health plc $405.77M $1.65 —

News headlines (Yahoo Finance, 1h cache)

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
2026-11-16 07:00 · Yahoo
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
2026-11-13 21:05 · Yahoo
Wall Street Analysts Think Oculis Holding AG (OCS) Could Surge 384.89%: Read This Before Placing a Bet
2026-11-12 13:55 · Yahoo
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
2026-11-09 07:00 · Yahoo
Down 21.1% in 4 Weeks, Here's Why Oculis Holding AG (OCS) Looks Ripe for a Turnaround
2026-11-06 13:35 · Yahoo
Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
2026-11-03 23:55 · Yahoo
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
2026-11-03 21:05 · Yahoo
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-11-02 14:00 · Yahoo
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
2026-11-02 08:18 · Yahoo
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
2026-10-29 09:39 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.